Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.
Brian Hill, MD, PhD, Cleveland Clinic
Advertisement
Articles by Brian Hill, MD, PhD, Cleveland Clinic
Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss recent data showing that the CAR T-cell production can be shortened.
Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss potential directions for CAR T-cell therapy in lymphomas.
Brian T. Hill, MD, PhD, and Craig Sauter, MD, discuss the promise of allogeneic CAR T-cell products.
Craig Sauter, MD, and Brian T. Hill, MD, PhD, address the issue of financial toxicity in CAR T-cell therapy.

Brian T. Hill, MD, PhD, discusses the safety profiles of BTK inhibitors in mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses the safety profiles of BTK inhibitors in mantle cell lymphoma.














Advertisement
Latest Updated Articles
Dr. Hill on the Safety Profiles of BTK Inhibitors in MCLDecember 7th 2020
SADAL Trial OverviewJuly 17th 2020
CAR T-Cell Therapy Clinical TrialsJuly 17th 2020
DLBCL Risk Assessment and Genetic SignaturesJuly 17th 2020
Therapy Initiation Prior to Cytogenetic Testing ResultsJuly 17th 2020
CAR T Cell Therapy in Relapsed/Refractory DLBCLJuly 17th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
4
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
5
